Adjuvant

Wuxal Foliar Nutrition: The Adjuvant Advantage

Order: Reorder
Duration: 2:45
Updated: 14 Nov 2012

Wuxal Foliar Nutrition for the agriculture industry is unlike any other product on the market. A unique advantage is the incorporation of seven key adjuvant features, which allow Wuxal to be much more efficacious than competitive foliar products, as highlighted in this video. Wuxal combines stable suspension technology in a high-load nutrient package. Together with its adjuvant package, Wuxal Foliar Nutrition is the ultimate tool for managing plant stress, delivering targeted nutrients during peak demand and efficiently addressing deficiencies in the plant at the right time. The seven core adjuvants are: Strong Chelating Agents, Surfactants, Stickers, Humectants, Anti-Evaporants, Buffering Agents and Miscibility. Learn more by visiting www.precisionlab.com/wuxal

http://wn.com/Wuxal_Foliar_Nutrition_The_Adjuvant_Advantage

Videographic - How adjuvants works

Order: Reorder
Duration: 0:58
Updated: 17 Jan 2013

Discover how adjuvant works with vaccines. For more details, read NRC's ST magazine Dimensions. www.nrc-cnrc.gc.ca

http://wn.com/Videographic_How_adjuvants_works

Modern Vaccine and Adjuvant Production and Characterization

Order: Reorder
Duration: 54:27
Updated: 12 Oct 2012

Vaccine production technology has evolved from using agents produced in animal tissue, eggs, and cultures to the use of virus-like particles (VLP). Challenges remain, however, in the analysis of key parameters for all types of vaccines. Many VLP vaccines can be characterized using techniques used for other biological drugs, however, more complex VLP vaccines offer unique analytical challenges. As both vaccines and adjuvant development and production technologies have evolved, so too have the methodologies used to meet more demanding manufacturing and regulatory standards. In this webinar you will learn about the use of multiple biophysical and biochemical approaches for candidate vaccine characterization and analytical characterization of vaccine adjuvant molecules and formulations, including the use of HPLC with charged aerosol detection.

http://wn.com/Modern_Vaccine_and_Adjuvant_Production_and_Characterization

..." style="float: right; margin-right: 25px;">

Adjuvant Opens Blood-Brain Barrier: Is In Our Kids' Vaccine

Order: Reorder
Duration: 7:02
Updated: 31 Jan 2013

The Canadian government has approved the unadjuvanted monovalent H1N1 vaccine, but not for toddlers and pregnant women, as we had been told they would. Instead, the 1.8 million shots of squalene-free vaccine will be given only to healthy adults and children age 10-65. Many parents who had been holding out for the unadjuvanted version seem to be under the mistaken impression that this is what is now being offered to their children. I wonder who will actually be receiving the 'special batch'? Will it be available on a first-come-first-serve basis, or only to a privileged group, as is the case in Germany? This is yet to be seen. The combination of squalene and Polysorbate 80 (surfactant) has been shown in animals to open the blood-brain barrier, giving neurotoxins such as mercury direct access to the central nervous system. While we are often reminded of how small the quantity of mercury in the vaccine is, I have never heard it mentioned that it will be given free access to our children's brains, thanks to the adjuvant. Monovalent vaccine package insert: not recommended for children under 3: www.gsk.ca Cochrane Review: Effectiveness of inactivated vaccine was similar to placebo in children 6 months to 2 years: www.cochrane.org Study describing how adjuvant can open blood-brain barrier: "Some studies of EAE (experimental allergic encephalomyelitis) in rodents report that peripheral injections of complete Freund's adjuvant (CFA), which contains heat-inactivated Mycobacterium ...

http://wn.com/Adjuvant_Opens_Blood-Brain_Barrier_Is_In_Our_Kids'_Vaccine

Adjuvant therapy for breast cancer

Order: Reorder
Duration: 22:22
Updated: 16 Nov 2012

This BJS paper is an analysis of data from the TEAM trial of adjuvant therapy for breast cancer. It concerns the different methods of treating breast cancer used in the various countries that enrolled patients into the study. In this podcast, first author, Dr Janine van Nes, is interviewed by Wendy Barnaby about the main results in this article. In response, Mr Malcolm Kell, consultant surgeon from Dublin, who acted as a reviewer for the BJS, discusses some of the issues raised by the research.

http://wn.com/Adjuvant_therapy_for_breast_cancer

Role of New and Existing Technologies and Adjuvants and Technology Transfer Models

Order: Reorder
Duration: 79:26
Updated: 03 Sep 2012

Presentations and discussion session. Presentations: 1) Roles of Existing Technologies and Adjuvants by Dr. Robin Robinson 2) Cell-Based and Recombinant Influenza Vaccine Manufacturing Technologies for Pandemic Influenza Preparedness by Dr. Armen Donabedian 3) Gates Foundation Influenza Vaccine Program by Dr. Douglas Holtzman 4) Examples of Vaccine Know-How Transfer by Dr. Jan Hendriks www.globalhealth.gov

http://wn.com/Role_of_New_and_Existing_Technologies_and_Adjuvants_and_Technology_Transfer_Models

Breast Cancer Adjuvant Therapy Treatment Types- Dr. David Margileth

Order: Reorder
Duration: 2:31
Updated: 09 Mar 2012

In this video, Dr. Margileth explains that adjuvant therapy is beyond their initial therapy of either mastectomy or lumpectomy. The major types of adjuvant therapies are either hormone therapy, such as the aromatase inhibitors, or drug therapy using the older drug Tamoxifen. Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor www.breastcanceranswers.com Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, www.breastcanceranswers.com This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.

http://wn.com/Breast_Cancer_Adjuvant_Therapy_Treatment_Types_Dr_David_Margileth

Adjuvant treatments for colorectal cancer - ESMO 2012

Order: Reorder
Duration: 3:29
Updated: 30 Oct 2012

Fortunato Ciardiello offers explanation on the failure of targeted therapy in adjuvant treatment of colorectal cancer. These studies were presented during ESMO 2012, the Congress of the European Society for Medical Oncology. Read all the news about the latest in cancer and oncology from the Congress here www.esmo.org The opinion expressed in this interview reflects that of the interviewee and does not necessarily express the official ESMO point of view.

http://wn.com/Adjuvant_treatments_for_colorectal_cancer_ESMO_2012

CME: Neo(adjuvant) Therapy for Gastric Cancer Module

Order: Reorder
Duration: 35:06
Updated: 09 Jan 2013

The worldwide incidence of new cases of Gastric Cancer is approximately 870000 cases per year, with 650000 deaths. Despite attempts at curative resection, survival for this disease remains poor. As a result, investigators have been evaluating adjuvant therapy to prevent recurrences and improve on overall survival. In this presentation Dr. Vincent Chung, FACP will undertake a scientific and clinical review that will profile and discuss the recent advances in the neo(adjuvant) therapy for Gastric Cancer. Release date: February 25-27, 2010 A City of Hope Continuing Medical Education e-Learning Module To obtain CME credit and learn more about this module, visit cityofhope.org To learn more about City of Hope Continuing Medical Education, visit cityofhope.org To view more CME modules, go to www.cityofhope.org ###################### CONNECT WITH CITY OF HOPE www.facebook.com www.twitter.com www.causes.com and more at www.cityofhope.org ABOUT CITY OF HOPE City of Hope is a leading medical research, treatment and education center dedicated to preventing, treating and curing cancer, diabetes, HIV/AIDS and other life-threatening diseases. Our mission is to quickly turn research ideas into cures that help save patients' lives all over the world. Learn more at www.cityofhope.org.

http://wn.com/CME_Neoadjuvant_Therapy_for_Gastric_Cancer_Module

Adjuvant And Neoadjuvant Therapy Side Effects-Dr. David Margileth

Order: Reorder
Duration: 5:54
Updated: 09 Mar 2012

In this video, Dr. Margileth explains that Adjuvant and Neoadjuvant chemotherapies are two major groups of toxicity: one are the problems that occur during the chemotherapy, or acute toxicities; and the other is late toxicities, that is, those toxicities after the chemotherapy has been completed in the treatment of breast cancer. Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor www.breastcanceranswers.com Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, www.breastcanceranswers.com This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.

http://wn.com/Adjuvant_And_Neoadjuvant_Therapy_Side_Effects-Dr_David_Margileth

Breast Cancer Adjuvant Therapy Types And Durations

Order: Reorder
Duration: 3:37
Updated: 09 Mar 2012

In this video, Dr. Margileth discusses that there are multiple variables involved in deciding which adjuvant chemotherapy to give and how long to it should be administered. Many of the trials are now ongoing and addressing these issues. Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor www.breastcanceranswers.com Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, www.breastcanceranswers.com This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.

http://wn.com/Breast_Cancer_Adjuvant_Therapy_Types_And_Durations

Primary Tumor Genetics and Adjuvant Therapies for Ocular Melanoma

Order: Reorder
Duration: 72:55
Updated: 03 Aug 2012

July 30, 2012 - Targeted toward patients, their families and health care providers caring for ocular melanoma patients, this webinar provides the most up-to-date information on tumor genetics and adjuvant therapies for ocular melanoma. The webinar breaks down the complexities of genetic testing. It also defines adjuvant therapy, provides background on the theory of adjuvant therapy in melanoma, and discusses current clinical trials for adjuvant therapy in ocular melanoma. Presenters -- Ms. Susan Walther, genetic counselor specializing in ocular tumors at University of Pennsylvania who works closely with Dr. Carol Shields, Dr. Takami Sato and their teams. Dr. Richard Carvajal, a medical oncologist specializing in melanoma at Memorial Sloan-Kettering Cancer Center in New York. Dr. Sara Selig, director of CURE OM, the Melanoma Research Foundation's initiative focused on ocular melanoma, moderated the discussion.

http://wn.com/Primary_Tumor_Genetics_and_Adjuvant_Therapies_for_Ocular_Melanoma

Neoadjuvant And Adjuvant Chemotherapy: Which Is Better?

Order: Reorder
Duration: 4:42
Updated: 10 Aug 2012

The ideal time to use neoadjuvant therapy is when a cancer is very large or HER-2/neu positive, explains Dr. Harness. Both neoadjuvant therapy and adjuvant therapy have pros and cons, so you and your doctor must decide which is best for your situation. Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor www.breastcanceranswers.com Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, www.breastcanceranswers.com This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.

http://wn.com/Neoadjuvant_And_Adjuvant_Chemotherapy_Which_Is_Better?

Adjuvant Zoledronic Acid Reduces Breast Cancer Deaths

Order: Reorder
Duration: 2:45
Updated: 09 Dec 2011

Adding zoledronic acid to adjuvant endocrine therapy significantly improved disease-free and overall survival in premenopausal women with endocrine-receptor--positive early breast cancer at 7 years' follow-up in the Austrian Breast and Colorectal Cancer Study Group-12 trial. Dr. Michael Gnant describes the results in this interview at the San Antonio Breast Cancer Symposium.

http://wn.com/Adjuvant_Zoledronic_Acid_Reduces_Breast_Cancer_Deaths

Aerial InterLock® Adjuvant Aerial Application Demonstration

Order: Reorder
Duration: 1:45
Updated: 15 May 2012

InterLock® is a drift reducing and deposition adjuvant that benefits aerial as well as ground applications. High speed cameras on the airplane and the ground show how adding InterLock® adjuvant helps reduce the amount of fine droplets and improves spray deposition on the plants.

http://wn.com/Aerial_InterLock®_Adjuvant_Aerial_Application_Demonstration

Adjuvant therapy for breast cancer video

Order: Reorder
Duration: 1:43
Updated: 02 Jun 2011

In this video from the National Comprehensive Cancer Network (NCCN), breast cancer expert Harold Burstein, MD, PhD, of the Dana-Farber Cancer Institute, explains adjuvant breast cancer therapy. The right choice of adjuvant therapy, especially drug therapy (chemotherapy), for breast cancer depends on whether the tumor is estrogen or progesterone positive or negative. For more information on the best treatment for breast and other cancers, including the NCCN Guidelines for Patients, visit www.NCCN.com. The NCCN is a not-for-profit alliance of 21 leading cancer centers—including Dana-Farber Cancer Institute—dedicated to improving cancer care.

http://wn.com/Adjuvant_therapy_for_breast_cancer_video

Adjuvant Chemotherapy Boosts Survival in Locoregional Recurrent Breast Cancer

Order: Reorder
Duration: 3:18
Updated: 10 Dec 2012

The CALOR trial settled a longstanding dispute in the management of women after excision of local or regional breast cancer recurrences. Bruce Jancin interviews Dr. Stefan Aebi on findings presented at the 2012 San Antonio Breast Cancer Symposium. For ongoing coverage of the meeting, visit www.oncologyreport.com.

http://wn.com/Adjuvant_Chemotherapy_Boosts_Survival_in_Locoregional_Recurrent_Breast_Cancer

Improving Patient Outcomes: Adjuvant Therapy for Breast Cancer

Order: Reorder
Duration: 38:47
Updated: 01 Nov 2012

Part 1 of 3 - St. Gallen 2011: Targeted Therapies in Breast Cancer - Piecing Together Ways to Improve Patient's Outcomes - Dr. Kimberly Blackwell St. Gallen March 2011- Satellite symposium. The approaches to, and options for, the management of breast cancer are continually evolving. This is part 1 of 3 - Dr. Kimberly Blackwell discusses the "Optimal Endocrine Therapy Strategy for Early Breast Cancer".

http://wn.com/Improving_Patient_Outcomes_Adjuvant_Therapy_for_Breast_Cancer

ASCO 2009: Bevacizumab and standard adjuvant chemotherapy

Order: Reorder
Duration: 8:05
Updated: 26 Oct 2010

ASCO 2009: Bevacizumab and standard adjuvant chemotherapy: no improvement in disease-free survival for early-stage colon cancer. Dr Norman Wolmark - Chairman Dept of Human Oncology, Allegheny General Hospital, US ASCO press conference: Adding bevacizumab (avastin) to standard adjuvant chemotherapy does not improve disease-free survival for early-stage colon cancer

http://wn.com/ASCO_2009_Bevacizumab_and_standard_adjuvant_chemotherapy

AgriSolutions™ InterLock® Adjuvant

Order: Reorder
Duration: 3:38
Updated: 20 Apr 2012

http://wn.com/AgriSolutions™_InterLock®_Adjuvant

ASCO: Trial compares common adjuvant treatments for pancreatic cancer

Order: Reorder
Duration: 4:32
Updated: 05 Jun 2010

Dr. John Neoptolemos - University of Liverpool, Liverpool, UK - speaking at the ASCO 2009 press conference: A phase III trial comparing the adjuvant treatments most commonly used for pancreatic cancer in the United States and Europe (gemcitabine and 5- FU/FA, respectively) found that there is no difference in survival between the two regimens, though gemcitabine was associated with fewer side effects.

http://wn.com/ASCO_Trial_compares_common_adjuvant_treatments_for_pancreatic_cancer

Uptake Technology's Adjuvant Advantage

Order: Reorder
Duration: 2:44
Updated: 15 Aug 2012

Uptake Technology™ is a high load foliar nutrition that provides more essential plant nutrition at lower use rates than any other product. Field-tested and backed by university research, Uptake Technology products provide better performance and value than industry leaders. The unique adjuvant package in Uptake Technology enhances performance for golf course superintendents and sports turf managers. *Note: Not all analyses produce buffering results shown in video. Contact Precision Laboratories for more details or visit www.precisionlab.com/uptake

http://wn.com/Uptake_Technology's_Adjuvant_Advantage

Adjuvant Treatment May Not Be Right for All Patients

Order: Reorder
Duration: 3:44
Updated: 21 Dec 2010

In this video blog, Dr. John Marshall talks about microsatellite instability, a marker that may reveal which patients with early colorectal cancer should forgo standard adjuvant treatment.

http://wn.com/Adjuvant_Treatment_May_Not_Be_Right_for_All_Patients